Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1919 1
1923 1
1924 1
1925 2
1928 2
1945 2
1946 7
1947 12
1948 12
1949 9
1950 5
1951 14
1952 12
1953 20
1954 16
1955 13
1956 19
1957 9
1958 6
1959 13
1960 19
1961 20
1962 27
1963 29
1964 30
1965 48
1966 59
1967 92
1968 117
1969 114
1970 128
1971 157
1972 194
1973 236
1974 256
1975 951
1976 1087
1977 1097
1978 1208
1979 1411
1980 1613
1981 1871
1982 1984
1983 2635
1984 2894
1985 3318
1986 3696
1987 4258
1988 4674
1989 6075
1990 6611
1991 7555
1992 8359
1993 9607
1994 10788
1995 12249
1996 13758
1997 15111
1998 16973
1999 19122
2000 21990
2001 24363
2002 27217
2003 30938
2004 36176
2005 40416
2006 45876
2007 50464
2008 55928
2009 60584
2010 69659
2011 79198
2012 88208
2013 96381
2014 104791
2015 113256
2016 120178
2017 127264
2018 135318
2019 146177
2020 169282
2021 190247
2022 192534
2023 189008
2024 211736
2025 279349
2026 278478
2027 1481

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,833,283 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: 23455478
Page 1
Emerging Targets in Non-Small Cell Lung Cancer.
Liu L, Soler J, Reckamp KL, Sankar K. Liu L, et al. Int J Mol Sci. 2024 Sep 18;25(18):10046. doi: 10.3390/ijms251810046. Int J Mol Sci. 2024. PMID: 39337530 Free PMC article. Review.
New molecular drivers continue to emerge as promising therapeutic targets, including KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate receptor alpha, ITGB6, and PRMT5. In this review, we summarize the emerging molecular targets with a potential clinical impact in adva …
New molecular drivers continue to emerge as promising therapeutic targets, including KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate r …
Chasing molecular glue degraders: screening approaches.
Domostegui A, Nieto-Barrado L, Perez-Lopez C, Mayor-Ruiz C. Domostegui A, et al. Chem Soc Rev. 2022 Jul 4;51(13):5498-5517. doi: 10.1039/d2cs00197g. Chem Soc Rev. 2022. PMID: 35723413 Review.
In particular, molecular glue degraders are monovalent compounds that orchestrate interactions between a target protein and an E3 ubiquitin ligase, prompting the proteasomal degradation of the former. This and other pharmacological strategies of targeted protein deg …
In particular, molecular glue degraders are monovalent compounds that orchestrate interactions between a target protein and an E3 ubi …
Targeting the undruggables-the power of protein degraders.
Zhang C, Liu Y, Li G, Yang Z, Han C, Sun X, Sheng C, Ding K, Rao Y. Zhang C, et al. Sci Bull (Beijing). 2024 Jun 15;69(11):1776-1797. doi: 10.1016/j.scib.2024.03.056. Epub 2024 Mar 29. Sci Bull (Beijing). 2024. PMID: 38614856 Free article. Review.
Undruggable targets typically refer to a class of therapeutic targets that are difficult to target through conventional methods or have not yet been targeted, but are of great clinical significance. ...Among them, targeted protein degradation te …
Undruggable targets typically refer to a class of therapeutic targets that are difficult to target through conventional …
The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I, Verrecchia F, Crenn V, Redini F, Trichet V. Corre I, et al. Cells. 2020 Apr 15;9(4):976. doi: 10.3390/cells9040976. Cells. 2020. PMID: 32326444 Free PMC article. Review.
Consequently, efforts to improve treatments using targeted therapies have faced this lack of specific osteosarcoma targets. Nevertheless, these tumors are inextricably linked to their local microenvironment, composed of bone, stromal, vascular and immune cells and t …
Consequently, efforts to improve treatments using targeted therapies have faced this lack of specific osteosarcoma targets. Ne …
Synthetic Lethality in Cancer Therapeutics: The Next Generation.
Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN. Setton J, et al. Cancer Discov. 2021 Jul;11(7):1626-1635. doi: 10.1158/2159-8290.CD-20-1503. Epub 2021 Apr 1. Cancer Discov. 2021. PMID: 33795234 Free PMC article. Review.
Recent technological advances have led to an inflection point in our understanding of genetic interaction networks and ability to identify a wide array of novel SL drug targets. Here, we review concepts and lessons emerging from first-generation trials aimed at testing SL …
Recent technological advances have led to an inflection point in our understanding of genetic interaction networks and ability to identify a …
Electrophilic warheads in covalent drug discovery: an overview.
Péczka N, Orgován Z, Ábrányi-Balogh P, Keserű GM. Péczka N, et al. Expert Opin Drug Discov. 2022 Apr;17(4):413-422. doi: 10.1080/17460441.2022.2034783. Epub 2022 Feb 6. Expert Opin Drug Discov. 2022. PMID: 35129005 Review.
The warheads are discussed by targeted residues, mechanism and selectivity, and analyzed through three different datasets including our collection of warheads, the CovPDB database, and the FDA approved covalent drugs. ...However, versatile, selective warheads are not avail …
The warheads are discussed by targeted residues, mechanism and selectivity, and analyzed through three different datasets including o …
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Tang T, et al. Signal Transduct Target Ther. 2021 Feb 20;6(1):72. doi: 10.1038/s41392-020-00449-4. Signal Transduct Target Ther. 2021. PMID: 33608497 Free PMC article. Review.
More importantly, we highlight the critical role of tumor immune microenvironment regulators in tumor immune surveillance, immunological evasion, and the potential for their further translation into clinical practice. Based on their general targetability in clinical therap …
More importantly, we highlight the critical role of tumor immune microenvironment regulators in tumor immune surveillance, immunological eva …
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.
Wang C, Zhang Y, Chen W, Wu Y, Xing D. Wang C, et al. Mol Cancer. 2024 May 21;23(1):110. doi: 10.1186/s12943-024-02024-9. Mol Cancer. 2024. PMID: 38773495 Free PMC article. Review.
Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention over the last 10 years, representing a burgeoning therapeutic approach with the potential to address pathogenic proteins that have historically posed challenges for traditional small-mol …
Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention over the last 10 years, representing a burgeon …
Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
Chen Y, Tandon I, Heelan W, Wang Y, Tang W, Hu Q. Chen Y, et al. Chem Soc Rev. 2022 Jul 4;51(13):5330-5350. doi: 10.1039/d1cs00762a. Chem Soc Rev. 2022. PMID: 35713468 Free PMC article. Review.
Proteolysis Targeting Chimeras (PROTACs), an emerging therapeutic entity designed to degrade target proteins by hijacking the ubiquitin-proteasome system, have the potential to revolutionize the healthcare industry. ...These improved delivery strategies can eliminat …
Proteolysis Targeting Chimeras (PROTACs), an emerging therapeutic entity designed to degrade target proteins by hijacking the …
Mutations de l'ADN dans les cholangiocarcinomes : cibler IDH1 et autres mutations.
Valéry M, Cervantes B, Smolenschi C, Boige V, Ducreux M, Cohen R, Hollebecque A. Valéry M, et al. Bull Cancer. 2022 Nov;109(11S):11S21-11S27. doi: 10.1016/S0007-4551(22)00465-9. Bull Cancer. 2022. PMID: 36535759 Review. French.
Some of these alterations are potential therapeutic targets. To date, only ivosidenib and pemigatinib, targeting IDH1 mutations and FGFR2 fusions respectively, are approved in France for pre-treated patients with these molecular alterations. Many other potentially …
Some of these alterations are potential therapeutic targets. To date, only ivosidenib and pemigatinib, targeting IDH1 mutation …
2,833,283 results
You have reached the last available page of results. Please see the User Guide for more information.